Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2161 to 2175 of 7682 results

  1. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    Awaiting development [GID-TA11366] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Zoll ThermoGuard XP for Intravascular Temperature Management

      Status ...

    Medical technologies guidance
    Topic selection

  3. Natural Cycles for monitoring fertility

      Status ...

    Medical technologies guidance
    Topic selection

  4. Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

    Awaiting development [GID-TA11092] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development [GID-TA11094] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]

    Awaiting development [GID-TA11099] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]

    Awaiting development [GID-TA11101] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Children and young people with disabilities and severe complex needs: integrated health and social care support

    Awaiting development [GID-QS10146] Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development [GID-QS10144] Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Pelvic floor dysfunction

    Awaiting development [GID-QS10129] Expected publication date: TBC

    Quality standard
    Awaiting development

  11. High linear energy transfer radiation for carbon ion beam therapy

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  12. Differential Target Multiplexed Spinal Cord Stimulation (MT742)

      Status ...

    Medical technologies guidance
    Topic selection

  13. Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

    Awaiting development [GID-TA11025] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

    Awaiting development [GID-TA11466] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

    Awaiting development [GID-TA11491] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development